{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:18:39Z","timestamp":1788675519695,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-\u03b1), is widely used in treating inflammatory bowel diseases (IBD), including ulcerative colitis (UC). While generally well-tolerated, infliximab is associated with rare but significant adverse effects, including autoimmune hemolytic anemia (AIHA). This report describes the case of a 54-year-old male diagnosed with UC, who developed hemolytic anemia secondary to infliximab therapy after 1\u202fyear of treatment. During the infusion preceding the onset of anemia, the patient experienced a severe infusion reaction characterized by urticaria, bronchospasm, chills, fever, and pulsating headache. Laboratory findings confirmed hemolytic anemia with a positive direct and negative indirect Coombs tests. The patient responded well to corticosteroid therapy (prednisone at 1\u202fmg\/kg\/day for 30\u202fdays) and stopping anti-TNF-\u03b1, with hemoglobin levels improving from 7.2\u202fg\/dL at presentation to 14.6\u202fg\/dL after 1\u202fmonth. AIHA should be considered an uncommon but serious complication of infliximab therapy, necessitating careful monitoring, especially in patients treated for gastrointestinal indications. This case underscores the importance of recognizing and managing infusion-related complications of biologic therapies.<\/jats:p>","DOI":"10.3389\/fmed.2025.1548321","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:56:31Z","timestamp":1741766191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Gerolamo","family":"Bevivino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Scarozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Di Fonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zerboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iacopini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00054725-200305000-00005","article-title":"A lupus-like syndrome associated with infliximab therapy","volume":"9","author":"Klapman","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","volume":"2009","author":"Garratty","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1038\/ajg.2009.307","article-title":"Autoimmune hemolytic anemia associated with ulcerative colitis: response to infliximab","volume":"104","author":"Leo Carnerero","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ajg.2009.751","article-title":"Autoimmune hemolytic anemia associated with ulcerative colitis: the most important step is to induce complete remission","volume":"105","author":"Moln\u00e1r","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.amsu.2021.102768","article-title":"Remsima (a tumor necrosis factor (TNF)-\u03b1 inhibitor) induced hemolysis in a patient with Crohn\u2019s disease\u2014case report","volume":"69","author":"Al-Ansari","year":"2021","journal-title":"Ann Med Surg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn\u2019s disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14744\/nci.2017.77045","article-title":"Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis","volume":"5","author":"Mir","year":"2017","journal-title":"North Clin Istanb"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3390\/life12111784","article-title":"Autoimmune hemolytic anemia in inflammatory bowel disease-report of a case and review of the literature","volume":"12","author":"Toplicanin","year":"2022","journal-title":"Life"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/ccr3.2394","article-title":"Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: a case report","volume":"7","author":"Strik","year":"2019","journal-title":"Clin Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e00002","DOI":"10.14309\/crj.0000000000000002","article-title":"A case of Evan\u2019s syndrome induced by vedolizumab","volume":"6","author":"Jen","year":"2019","journal-title":"ACG Case Rep J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MCHD-0022-2015","article-title":"Anti-TNF Therapy","volume":"4","author":"Udalova","year":"2016","journal-title":"Microbiol Spectr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/ijd.IJD_579_17","article-title":"Causality or relatedness assessment in adverse drug reaction and its relevance in dermatology","volume":"63","author":"Pande","year":"2018","journal-title":"Indian J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1548321\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:56:33Z","timestamp":1741766193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1548321\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":21,"alternative-id":["10.3389\/fmed.2025.1548321"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1548321","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1548321"}}